BioSpace News Archive

Innovative partnership will provide broad-based healthcare coverage throughout Bergen and Passaic counties, enhancing the continuum of care for communities across the region

JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo

Harvest Health & Recreation, Inc., a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S. responded to the passage of the Secure and Fair Enforcement Banking Act of 2019.

The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma cells in animal models, according to City of Hope research published today in Science Translational Medicine.

STATinMED Research, a leading health economics and outcomes research (HEOR) company, announces Dr. Nora Janjan’s appointment as Chief Medical Officer. Dr. Janjan, formerly Professor at MD Anderson Cancer Center, will play a key role in STATinMED’s expansion within oncology and cardiology and will contribute her real-world clinical and HEOR expertise to research projects in all medical disciplines.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York, NY.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis’ presentation has been scheduled for Wednesday, October 2, 2019 at 8:55 AM EDT / 5:55 AM PDT.

Clinical remission rates at week 52 were superior with vedolizumab at 31.3% (n=120/383) versus 22.5% (n=87/386) with adalimumab (p=0.006).